RxDoctor Payments Data

Beth Britt

Nurse Practitioner · Bad Axe, MINPI 1366912321

Payments from drug & device makers

$2,660in general payments, 2019–2025

Across 138 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$509
  • Boehringer Ingelheim$340
  • Johnson & Johnson$290
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$290
  • Novartis$204
  • Pfizer$185
  • plus $843 from 15 others

What the payments were for

  • Food & beverage$2,660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,660 in reported general payments places this provider in the 90th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$29,348
Medicare patients
248
Services billed
589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban537$599,318
EntrestoSacubitril/Valsartan229$247,586
XareltoRivaroxaban200$222,953
JardianceEmpagliflozin207$211,720
Repatha SureclickEvolocumab230$135,561
FarxigaDapagliflozin Propanediol99$92,694
MultaqDronedarone Hcl17$32,197
Icosapent Ethyl59$21,578
BrilintaTicagrelor19$16,967
EdarbyclorAzilsartan Med/Chlorthalidone30$16,423
Praluent PenAlirocumab28$13,381
Rosuvastatin Calcium627$11,878
Atorvastatin Calcium581$9,859
Metoprolol Succinate502$9,700
Ezetimibe412$9,258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$185$599,318537 claims
NovartisEntresto$204$247,586229 claims
Johnson & JohnsonXarelto$290$222,953200 claims
Boehringer IngelheimJardiance$340$211,720207 claims
AstraZenecaFarxiga, Brilinta$109$109,661118 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$23$16,42330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Bad Axe

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →